Forbes Medi-Tech Announces Phytosterol Revenues of $1.15 Million

Forbes Medi-Tech Inc. has announced its results for the first quarter ended March 31, 2010. The comparative period for these results is the three-month period ended March 31, 2009. All amounts are in Canadian Dollars unless otherwise noted.

2010 OVERVIEW:
- Exchange Listings:

In January 2010, the Company received a Nasdaq Staff Deficiency Letter indicating that it did not meet The NASDAQ Capital Market initial listing standard and its common shares were subject to suspension. The Company provided the NASDAQ with a notice of appeal of the Nasdaq Staff Deficiency determination to a Hearings Panel.

In February 2010, the Company received notification that a NASDAQ Listing Qualifications Panel has determined to delist the Company's common shares from The NASDAQ Stock Market, effective February 18, 2010. With the delisting, the Company's common shares were immediately transferred for quotation to the Pink Sheets.

In April 2010, the Company received notification that its common stock was eligible for trading on the Over-the-Counter Bulletin Board ("OTCBB"), an electronic quotation service maintained by the Financial Industry Regulatory Authority ("FINRA"), effective on April 7, 2010. The Company's common shares continue to trade under the symbol FMTI.

- Going Concern
Management is of the view that there are sufficient financial resources to finance operations through the second quarter of 2010. This view is based on a number of factors and assumptions and includes the assumption that our expenditures will not exceed those currently planned, and that our revenues will meet or exceed our expectations.

The Company's future operations are completely dependent upon its ability to complete a strategic transaction such as a merger, acquisition, sale of business or other suitable transaction, and/or secure additional funds. If it is unable to close on a strategic transaction before it exhausts its available financial resources, then it may be unable to continue operations as a going concern and will have to consider winding up, dissolution or liquidation.

- FINANCIAL RESULTS:
The following table offers a summary of the financial results for the first quarter of 2010.
----------------------------------------------------------------------------------Summary: 3 month period 3 month period
(thousands of $ except per share ended March 31, ended March 31,
values and number of shares) 2010 2009
----------------------------------------------------------------------------------

Sales-phytosterol products $ 1,063 $ 615
Sales-finished goods 90 108
Licensing - 2
----------------------------------------------------------------------------------
Phytosterol revenues 1,153 725

Cost of Sales (982) (509)
Inventory allowances (58) 6
----------------------------------------------------------------------------------
113 222
Expenses (983) (1,419)
Other income 28 4,188
---------------------------------------------------------------------------
(Loss) / income from operations (842) 2,991

Income tax expense - (2)
---------------------------------------------------------------------------
Net (loss) / income and comprehensive
(loss) / income $ (842) $ 2,989
---------------------------------------------------------------------------

---------------------------------------------------------------------------
Weighted average number of shares 4,969,813 4,969,813
---------------------------------------------------------------------------

Net (loss) / income per share
Basic and diluted $ (0.17) $ 0.60
---------------------------------------------------------------------------

Revenues:
Phytosterol revenues include direct sales of phytosterol products (branded - Reducol(TM), non-branded sterol esters and sterols), sales of finished products containing Reducol(TM). Phytosterol revenues for the quarter ended March 31, 2010 totaled $1,153,000 compared with $725,000 for the quarter ended March 31, 2009. The increase is primarily due to a major customer returning to regular purchasing patterns whereas this customer was realigning inventories in first three months of 2009. The increase was partially offset by a decrease in sales to European customers and a decrease in sales by Forbes-Fayrefield of finished products.

Cost of Sales/ Margins:
For the quarter ended March 31, 2010, the Company realized a gross margin percentage of 10% on phytosterol revenues of $1,153,000, compared with a gross margin percentage of 31% on phytosterol revenues of $725,000 for the quarter ended March 31, 2009.

In the quarter ended March 31, 2010, $58,000 was charged to cost of sales, relating to valuation allowances on inventories. In the quarter ended March 31, 2009, $6,000 relating to valuation allowances was relieved from cost of sales. Prior to the impact of these allowances, in the quarter ended March 31, 2010 the Company realized a gross margin percentage of 15%, compared with a gross margin percentage of 30% for the quarter ended March 31, 2009.

The decrease in gross margin percentage is primarily due to a customer mix with lower margins and less favorable foreign exchange rates.

The Company continues to reduce operating expenses wherever possible. The reduction in expenses in the current quarter in comparison to the comparable quarter in the previous year is attributable to a reduced head count and other cost saving measures.

Liquidity & Capital Resources:
The Company's net cash and cash equivalents as of March 31, 2010 totaled $1,471,000 compared with $1,329,000 as at December 31, 2009. The Company had working capital of $3,099,000 at March 31, 2010 compared with $3,960,000 at December 31, 2009.

The going concern concept assumes that the Company will continue in operations for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Certain conditions, discussed below, currently exist which raise substantial doubt about the validity of this assumption.

The Company has sustained continuing operating losses since its formation. The Company's management is of the view that there are sufficient financial resources to finance operations through the second quarter of 2010. This view is based on a number of factors and assumptions and includes the assumption that its expenditures will not exceed those currently planned, and that its revenues will meet or exceed its expectations.

The Company's future operations are completely dependent upon its ability to complete a strategic transaction such as a merger, acquisition, sale of business or other suitable transaction, and/or secure additional funds. The market for any of these activities for companies such as Forbes has always been challenging. The outcome of these matters cannot be predicted at this time. Any possible strategic transactions to define the Company's future may require shareholder approval. If the Company is unable to close on a strategic transaction before it exhausts its available financial resources, then it may be unable to continue operations as a going concern and will have to consider winding up, dissolution or liquidation.

First Quarter Report
This news release includes by reference the Company's unaudited financial statements for the first quarter ended March 31, 2010 and the Management Discussion & Analysis (MD&A). More detailed information can be found in the MD&A and financial statements, which are being filed with applicable Canadian and U.S. regulatory authorities.

About Forbes Medi-Tech Inc.
Forbes Medi-Tech Inc. is a life sciences company focused on evidence-based nutritional solutions. A leader in nutraceutical technology, Forbes is a provider of value-added products and cholesterol-lowering ingredients for use in functional foods and dietary supplements. Forbes successfully developed and commercialized its Reducol(TM) plant sterol blend, which has undergone clinical trials in various matrices and has been shown to lower "LDL" cholesterol levels safely and naturally. Building upon established partnerships with leading retailers and manufacturers across the globe, Forbes helps its customers to develop private label and branded products. For more information, please visit www.forbesmedi.com.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish